Evidence map›Paper›PMID 41333211›Full record

ArticleFrontiers in oncology2025

Spatially fractionated radiotherapy combined with CapeOX and bevacizumab for postoperative pulmonary metastasis from urachal carcinoma: a case report.

Jian Fang, Aixin Wang, Quan Yao, Xinyi Liu, Weiyi Zhou, Jinyi Lang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jian FangDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Aixin WangDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Quan YaoDepartment of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Xinyi LiuDepartment of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Weiyi ZhouDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Jinyi LangDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urachal carcinoma is a rare and aggressive malignancy with limited treatment options, particularly in the metastatic setting. Standardized therapeutic protocols are lacking. This case report describes a 62-year-old female patient who developed pulmonary and mediastinal lymph node metastases more than four years after surgical resection of urachal carcinoma. For this case, a combined regimen of Spatially Fractionated Radiotherapy (SFRT), CapeOX (capecitabine plus oxaliplatin) chemotherapy, and bevacizumab targeted therapy was developed. The treatment course was complicated by grade 4 hematologic toxicity and radiation-induced esophagitis, both of which were successfully managed. To our knowledge, this represents the first documented application of SFRT in urachal carcinoma. Although significant tumor shrinkage was not observed, the patient achieved symptomatic relief, metabolic remission, and stable disease during follow-up.

Indexed as

lattice radiotherapypulmonary metastasissignet ring cell carcinomaspatially fractionated radiotherapyurachal carcinoma

Identifiers

PMID41333211
PMCPMC12665564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.